Latest News - Bristol-Myers Squibb
Top Corporates Hub
Bristol-Myers Squibb
3 Healthcare Stocks We Keep Off Our Radar
24.07.2026 16:33
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 9.7% gain over the past six months, beating the S&P 500 by 1.8 percentage points.
Will Moderna (MRNA) Report Negative Earnings Next Week? What You Should Know
24.07.2026 14:00
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth
23.07.2026 14:00
Bristol Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alexandria Real Estate Equities (ARE) Delivers 427,000 RSF Bristol Myers Squibb R And D Hub
22.07.2026 07:10
Alexandria Real Estate Equities (NYSE:ARE) has delivered a 427,000 RSF research and development facility for Bristol Myers Squibb at its San Diego megacampus. The new state-of-the-art R&D hub marks an operational milestone for the company and reflects demand from a large multinational pharmaceutical tenant. Alexandria Real Estate Equities focuses on life science and R&D campuses that serve large pharmaceutical and biotech companies. The new San Diego facility for Bristol Myers Squibb adds...
Bristol Myers, NVIDIA join forces to build life science’s ‘most powerful’ AI factory
21.07.2026 11:12
BMS enhances its AI computing power as big pharma race to stay competitive within the shifting global landscape.
Bristol Myers buys Nvidia's latest AI computing system for drug research
20.07.2026 11:01
Bristol Myers Squibb said on Monday it is buying the latest-generation computing system from chip company Nvidia to support its use of artificial intelligence across its drug discovery and development operations. The drugmaker said it will be the first life sciences company to buy an Nvidia DGX SuperPOD based on its Vera Rubin systems. The chipmaker unveiled its Vera Rubin architecture earlier this year as the successor to its current generation of AI computing systems.
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA
20.07.2026 10:59
PRINCETON, N.J., July 20, 2026--Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA
Bristol Myers Squibb Co (NYSE:BMY): A High Yield Dividend Stock Backed by Strong Profitability
18.07.2026 12:20
Dividend investing requires balancing income with long-term safety. Discover how the Best Dividend Stocks screen identifies quality payers like Bristol Myers Squibb (BMY), offering a 4.35% yield supported by strong profitability and a cheap valuation near a 10 P/E ratio.
Bristol Myers Squibb (BMY) Wins FDA Review For Mezigdomide In Multiple Myeloma
16.07.2026 02:13
FDA has accepted Bristol Myers Squibb's New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. The filing is supported by a Phase 3 trial that showed a meaningful improvement in progression free survival for this patient group. This decision marks a key regulatory milestone for NYSE:BMY's oncology pipeline and could influence how investors view its future revenue mix. Bristol-Myers Squibb enters this news cycle...
Septa Pharmaceuticals Inc. Acquires CeeNU® (Lomustine) from Bristol Myers Squibb, Canada
15.07.2026 11:00
Septa Pharmaceuticals Inc., a rapidly growing leader in the Canadian healthcare sector, is proud to announce the successful acquisition of CeeNU® (Lomustine) from Bristol Myers Squibb, Canada as of June 29th, 2026. This strategic acquisition marks a significant milestone in Septa's ongoing expansion and underscores its unwavering dedication to strengthening its specialty oncology pharmaceutical portfolio. CeeNU® (Lomustine) is an established and highly valued alkylating agent utilized primarily
Eli Lilly-Backed Novel Cancer Therapy Firm Raises $315 Million
15.07.2026 10:00
(Bloomberg) -- AdvanCell Pty, a biotechnology firm backed by Eli Lilly & Co., has raised $315 million in new funding, underscoring investor confidence in its experimental cancer therapy.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsTrump Drops 20% Fee for Hormuz Cargo After Gulf PressureUS Hits Iran With Strikes, Blockade as Trump Plans Hormuz ChargeOpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI Companion‘We Faltered’: IBM Plunges M
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
13.07.2026 13:10
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Agenus surges on study pivot; Apnimed lines up an IPO
13.07.2026 11:46
Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
13.07.2026 10:59
PRINCETON, N.J., July 13, 2026--U.S. FDA Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?
10.07.2026 18:10
CYTK enters a new era after Myqorzos FDA approval, with early US uptake, European expansion and lifecycle studies fueling its commercial momentum.
Start Investing At 60 And Retire On Dividends Forever
10.07.2026 08:00
Retire on dividends even if you started late. Build a 6% high-yield portfolio, reduce sequence risk, and see top picks like ENB, OHI & BMYâread now.
Bristol Myers Squibb (BMY) Expands QUILS Lung Cancer Detection Model Beyond Kentucky
09.07.2026 13:18
Bristol Myers Squibb (NYSE:BMY) Foundation’s QUILS initiative is reshaping lung cancer early detection in Kentucky. The program is now serving as a model for similar efforts in Mississippi and Nevada. QUILS targets earlier identification of lung cancer in regions with some of the highest reported rates in the country. Bristol Myers Squibb operates as a global biopharmaceutical company with a focus on oncology, immunology, and cardiovascular treatments. The QUILS initiative adds a public...
ABBV Leads Its Peer Group. You Pay For That
09.07.2026 13:13
AbbVie's stock commands a king's ransom, but its performance metrics rule the kingdom, leaving investors to ask if they are buying at the top of the reign.
Is Janux Therapeutics’ (JANX) Russell Index Exit Quietly Rewriting Its Investor Base and Story?
09.07.2026 09:10
In late June 2026, Janux Therapeutics, Inc. was removed from several Russell growth and small-cap benchmarks, including the Russell 2000 Growth, 2500 Growth, Small Cap Comp Growth, 3000E Growth, and 3000 Growth indexes. This broad index removal matters because it can force index-tracking funds to rebalance, potentially changing who holds the stock and how it trades. Next, we’ll examine how Janux’s removal from multiple Russell growth indexes shapes the company’s investment narrative for...
Is Bristol Myers Squibb’s Shift Into Value-Defensive Indices Reshaping The Investment Case For BMY?
09.07.2026 00:21
In late June 2026, Bristol-Myers Squibb was removed from several Russell growth benchmarks and added to the Russell 1000 Value-Defensive and Russell 1000 Defensive indices, marking a reclassification of the stock within major index families. This shift signals that index providers now view Bristol-Myers Squibb more as a defensive, income-oriented holding than a growth-driven pharmaceutical name, aligning with its dividend profile and efforts to manage patent expirations. Next, we will...